Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 11 New Products, 7 APIs Recommended for NHI Price Listing
September 7, 2009
- Basen Recommended for Approval for Prevention of Type 2 Diabetes
September 7, 2009
- Cervarix Recommended for Approval
September 7, 2009
- REGULATORY NEWS IN BRIEF
September 7, 2009
- Full-Scale Flu Epidemic May Have Begun: Health Minister
August 31, 2009
- Makers' FY2009 1st Qtr Business Roundup -2-
August 31, 2009
- GSK Starts Adjusting Shipments of Relenza due to Rush of Orders
August 31, 2009
- Makers' FY2009 1st Qtr Business Roundup -1-
August 31, 2009
- Sales of Ethical Drugs Up 7.9% in June: Crecon
August 31, 2009
- Kowa Licenses Livalo to MTPC in Taiwan, Indonesia
August 31, 2009
- SELF-MEDICATION NEWS IN BRIEF
August 31, 2009
- DSP to Transform Itself into Global Research-Driven Pharma: President Tada
August 31, 2009
- G&G to Develop Overseas Business in Earnest
August 31, 2009
- Allopurinol + Uralyt Combination Useful for Management of MetS
August 31, 2009
- SSP to Place Top Priority on Operating Profit Rate
August 31, 2009
- R&D NEWS IN BRIEF
August 31, 2009
- REGULATORY NEWS IN BRIEF
August 31, 2009
- Everolimus Approved in EU: Novartis
August 31, 2009
- Japan, China, South Korea Start Working-Level Regulatory Consultations
August 31, 2009
- Korosho to Promote Sharing of Know-how to Promote Use of Generics
August 31, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…